Ustekinumab-Auub

Introduction Overview

Generic Name

ustekinumab-auub

Brand Name

Wezlana

Dosage Form

Autoinjector, Pre-Filled Syringe, Single-Dose Vial

Drug Class

Interleukin inhibitors

Pharmacokinetics

Absorption:
Ustekinumab-auub (Wezlana) is administered subcutaneously, and its absorption is relatively slow with peak serum concentrations typically occurring approximately 7 to 14 days post-injection. The bioavailability is estimated to be about 57% following subcutaneous administration, which reflects partial absorption and first-pass degradation mechanisms inherent to monoclonal antibodies. Factors such as injection site and local blood flow may modestly influence absorption kinetics. Clinical studies demonstrate consistent pharmacokinetics in patients with autoimmune inflammatory conditions treated with Wezlana, with steady-state levels reached after repeated administration.

Distribution:
Ustekinumab demonstrates a limited volume of distribution consistent with large protein therapeutics, generally approximating plasma volume. The drug distributes primarily within the vascular and interstitial spaces without significant penetration into intracellular compartments or crossing the blood-brain barrier. Ustekinumab binds specifically to interleukin receptor targets in affected tissues but does not exhibit significant nonspecific tissue binding. Protein binding is through specific molecular interaction rather than nonspecific plasma protein binding.

Metabolism:
As a monoclonal antibody, ustekinumab is metabolized via proteolytic enzymatic degradation pathways typical to endogenous IgG antibodies. This catabolism occurs predominantly in the reticuloendothelial system and target tissues, resulting in small peptides and amino acids that are recycled or eliminated. The drug is not metabolized by cytochrome P450 enzymes, minimizing the risk of classical hepatic drug-drug interactions. Immunogenicity with anti-drug antibody formation can influence pharmacokinetics by increasing clearance in some patients.

Elimination:
Ustekinumab is eliminated through normal IgG clearance pathways, including receptor-mediated endocytosis and lysosomal degradation. The elimination half-life is approximately 3 weeks (approximately 15 to 45 days), which supports dosing intervals every 8 to 12 weeks depending on indication and clinical response. Renal or hepatic impairment does not significantly alter elimination kinetics due to the non-renal, non-hepatic catabolic route. Clearance can be increased in patients developing antibodies against ustekinumab, potentially decreasing therapeutic efficacy.

Dosage Forms

Available Dosage Forms:
Wezlana is available in the following dosage forms and strengths, designed for subcutaneous injection:
- Autoinjector: 45 mg/0.5 mL, 90 mg/mL
- Pre-Filled Syringe: 45 mg/0.5 mL, 90 mg/mL
- Single-Dose Vial: 45 mg/0.5 mL, 130 mg/26 mL (5 mg/mL)

Dosages for Adults and Adolescents:
The dosing regimen for Wezlana varies depending on the indication:
- Plaque psoriasis and psoriatic arthritis: initial dose followed by a second dose at week 4, then maintenance doses every 12 weeks thereafter.
- Crohn's disease and ulcerative colitis: dosing starts with an initial intravenous infusion followed by subcutaneous maintenance doses every 8 weeks.
Dosing may be weight-based, with patients weighing over 100 kg typically receiving higher doses.
For patients aged 6 years and older with moderate to severe plaque psoriasis or psoriatic arthritis, dosing parallels adult regimens adjusted by weight and clinical response.

Specific Patient Populations:
Special considerations for dosing include:
- Pediatric patients (≥6 years) receive weight-based dosing similar to adults, with clinical monitoring.
- No dosage adjustment is required for mild to moderate renal or hepatic impairment.
- Immunogenicity monitoring is advised, as anti-drug antibodies may alter dose requirements.
- Patients with active infections should delay therapy initiation until resolved.
- Treatment should be administered under healthcare provider supervision, with careful patient education on self-injection techniques when using autoinjectors or prefilled syringes.

Mechanism Of Action

Ustekinumab-auub (Wezlana) is a fully human IgG1 kappa monoclonal antibody that selectively binds to the p40 protein subunit shared by the pro-inflammatory cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23). By targeting the p40 subunit, Wezlana effectively inhibits the biological activity of both IL-12 and IL-23, which play pivotal roles in the pathogenesis of autoimmune inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

The blockade of IL-12 and IL-23 cytokines interrupts the differentiation and activation of naïve T-helper cells into pathogenic Th1 and Th17 cells, which are responsible for orchestrating inflammatory responses through production of cytokines like interferon-gamma, IL-17, and tumor necrosis factor-alpha. This immunomodulation reduces the inflammatory cascade that results in the characteristic tissue damage and symptomatology of the targeted diseases.

On a cellular level, by preventing IL-12 and IL-23 binding to their receptors on immune cells, Wezlana suppresses the activation and proliferation of autoreactive T-cells and downstream inflammatory mediators. This leads to significant reduction in skin plaque formation, joint inflammation, and intestinal mucosal damage as demonstrated in clinical efficacy studies.

Compared to other interleukin inhibitors targeting distinct subunits or cytokines, ustekinumab's dual inhibition of IL-12 and IL-23 provides a broader immunomodulatory effect. Clinical trials have shown that this mechanism confers durable responses with favorable safety profiles for both cutaneous and gastrointestinal autoimmune conditions. Ongoing research evaluates optimization of immunological pathways for improved patient outcomes.

Pharmacological Actions

Selective inhibition of interleukin-12 (IL-12) and interleukin-23 (IL-23) signaling pathways.
Modulation of T-cell mediated immune responses by blocking differentiation of Th1 and Th17 cells.
Reduction of pro-inflammatory cytokine production (e.g., IFN-gamma, IL-17, TNF-alpha).
Suppression of inflammation in skin, joints, and gut mucosa in autoimmune diseases.
Mitigation of autoimmune-driven tissue damage through targeted immunomodulation.
Long half-life allowing sustained immunologic effect with infrequent dosing intervals.
Reduction in epidermal hyperplasia and plaque formation in psoriasis.
Decrease in synovial inflammation and joint destruction in psoriatic arthritis.
Improvement of mucosal healing and reduction of symptoms in Crohn's disease and ulcerative colitis.
Minimal off-target immunosuppression compared to broad-acting immunosuppressants.
Potential to reduce flares and maintain disease remission.
Biologic therapy with engineered human monoclonal antibody structure to reduce immunogenicity.

Therapeutic Or Clinical Uses

Treatment of moderate to severe plaque psoriasis in adults and children aged 6 years and older.
Management of active psoriatic arthritis in adult patients.
Treatment of moderately to severely active Crohn's disease in adults.
Treatment of moderately to severely active ulcerative colitis in adults.
Use as a systemic therapy alternative for patients refractory to phototherapy or other systemic agents.
Reduction in symptoms and inflammatory lesions associated with autoimmune skin disorders.
Improvement of joint function and reduction of structural damage in psoriatic arthritis patients.
Induction and maintenance of remission in inflammatory bowel diseases.
Modulation of immune response in patients with chronic inflammatory diseases through cytokine inhibition.
Treatment option for patients intolerant or unresponsive to tumor necrosis factor (TNF) inhibitors.
Off-label investigation in other IL-12/23-mediated conditions such as hidradenitis suppurativa or other autoimmune diseases.
Part of biosimilar therapeutic options providing potential cost savings while maintaining efficacy.

Side Or Adverse Effects

Upper respiratory tract infections including bronchitis and inflamed sinuses.
Injection site reactions such as redness and itching.
Gastrointestinal symptoms including diarrhea, nausea, vomiting, and stomach pain.
Common cold symptoms, fever, and flu-like illness.
Headache and tiredness (fatigue).
Vaginal candidiasis and other fungal infections.
Urinary tract infections.
Potential for serious infections including tuberculosis and opportunistic infections.
Rare reports of hypersensitivity or allergic reactions including hives, swelling, and anaphylaxis.
Possibility of malignancy, particularly non-melanoma skin cancer with prolonged use.
Neurological adverse effects such as Posterior Reversible Encephalopathy Syndrome (PRES) manifesting as headache, confusion, seizures, or vision changes.
Changes in bowel habits, including severe diarrhea or constipation.
Muscle pain and weight loss associated with infection risk.
Potential for the development of anti-drug antibodies altering efficacy.
Possible exacerbation of latent infections or reactivation of tuberculosis.

Precautions

Screen for active or latent tuberculosis prior to initiation of therapy.
Avoid administration within 12 months before or after BCG vaccination.
Use caution in patients with a history of chronic or recurrent infections.
Perform regular skin examinations due to increased risk of non-melanoma skin cancer.
Avoid use in patients with known hypersensitivity to ustekinumab or excipients.
Be alert for symptoms indicative of serious infections during treatment and promptly evaluate.
Latex allergy consideration as prefilled syringe needle covers contain latex.
Avoid live vaccines during treatment and for 12 months post-therapy; assess vaccination status before initiation.
Monitor neurologic status for signs of PRES or other rare neurologic adverse events.
Pregnancy registry enrollment recommended for patients exposed to ustekinumab during pregnancy.
Caution advised in breastfeeding women; discuss alternative feeding options.
Adjust immunosuppressive co-therapy cautiously when combining with other agents.
Avoid abrupt discontinuation without medical guidance to prevent disease flare.
Patients should be counseled on recognizing early signs of infection or other adverse events.
Consider immunogenicity impact and monitor for decrease in therapeutic effect.

Warnings

Serious infections including sepsis, bacterial, viral, and fungal infections have been reported; immediate medical attention needed if infection signs appear.
Do not administer live vaccines during treatment; live vaccines may cause serious infections in immunocompromised patients.
Avoid BCG vaccination within 12 months before or after treatment with Wezlana.
Potential increased risk of malignancies, particularly non-melanoma skin cancer; periodic skin exams recommended.
Posterior Reversible Encephalopathy Syndrome (PRES), a rare but serious neurological condition, may occur; monitor for headache, confusion, seizures, and vision problems.
Hypersensitivity reactions including anaphylaxis warrant discontinuation and emergency intervention.
Immunosuppression induced by Wezlana may predispose patients to opportunistic infections.
Monitor patients with previous malignancies carefully as data on cancer risk in this population is limited.
Use caution in patients with pre-existing chronic infections or immunodeficiency.
Potential for worsening Crohn's disease symptoms has been reported; clinical monitoring essential.
Serious allergic reactions may involve swelling of the face, lips, tongue, or throat and require immediate medical care.
Do not switch between reference product and biosimilar without appropriate clinical evaluation due to potential variations.
Risk of concomitant immunosuppressive therapy increasing infection risk.
Elective surgery patients should be evaluated as suppression of immune response may increase perioperative infection risk.
Pregnancy usage data insufficient to establish safety; use only if clearly needed and benefits outweigh risks.

Contraindication

Known hypersensitivity to ustekinumab or any component of the formulation.
Active tuberculosis or any severe, active infection.
Use within 12 months following BCG vaccine administration.
Patients with history of hypersensitivity reactions to prior biologic therapies based on ustekinumab.
Concurrent use with live vaccines or administration of live vaccines during therapy.
Not recommended for use in patients with sepsis or uncontrolled severe infections.
Contraindicated in patients with known allergic reactions to latex if using prefilled syringe with latex needle cover.
Use contraindicated in patients with active malignancy until resolved or adequately treated.
Not advised in individuals with a history of demyelinating diseases due to immunomodulatory effects.
Avoid in patients with documented hypersensitivity to monoclonal antibodies.
Contraindicated in patients with compromised immune systems due to risk of severe infections.
Failure to complete tuberculosis screening prior to therapy initiation contraindicates use.
Contraindicated for pediatric patients under 6 years of age due to lack of data.
Not indicated for acute infections or in post-exposure prophylaxis settings for infections.
Patients with unstable or severe heart failure should avoid biologic agents without specialist consultation.

Drug Interactions

Potential increased risk of infection when combined with other immunosuppressive agents such as azathioprine, cyclosporine, methotrexate, sirolimus, or tacrolimus.
Possible interaction with anticoagulants such as warfarin necessitating careful monitoring of coagulation parameters.
Oral corticosteroids (e.g., dexamethasone, methylprednisolone, prednisone) may increase immunosuppression when used concomitantly with Wezlana.
No significant cytochrome P450 mediated drug interactions expected due to monoclonal antibody metabolism.
Live vaccines should be avoided during and for at least 12 months following therapy to prevent serious infections.
Vaccination with non-live vaccines may have reduced therapeutic efficacy during ustekinumab treatment.
Concomitant use with other biologics not recommended due to compounded immunosuppressive effects and infection risk.
No reported interactions with common over-the-counter medications or herbal supplements, but clinical vigilance advised.
Potential altered pharmacodynamics when combined with other biologic or targeted synthetic DMARDs.
Possible interference with immunologic or diagnostic tests due to circulating monoclonal antibodies.
Interactions with drugs that prolong immunosuppression may necessitate dose adjustments and increased infection monitoring.
Coadministration with BCG vaccine contraindicated due to infection risk.
No specific noted interactions with antacids or gastrointestinal agents.
Limited data on interactions with antiviral treatments; caution advised in patients on chronic antiviral therapy.
Potential drug interactions with agents modifying immune system function warrant clinical monitoring.

Preparations Of The Drug

Autoinjector devices containing ustekinumab-auub at concentrations of 45 mg/0.5 mL and 90 mg/mL for patient self-administration.
Sterile pre-filled syringes available in 45 mg/0.5 mL and 90 mg/mL strength for subcutaneous injection.
Single-dose vials formulated at 45 mg/0.5 mL and 130 mg/26 mL (5 mg/mL) for intravenous or subcutaneous administration as indicated.
Parenteral formulations free from preservatives suitable for single-dose use to ensure safety and efficacy.
Packaging designed for protection against light and temperature excursions, recommending storage refrigerated between 2°C to 8°C.
Ready-to-use presentations minimizing preparation time and contamination risk.
Needle cover of prefilled syringes contains latex; alternative devices available for patients with latex allergy.
All formulations are supplied with dosage instructions and patient information leaflets per regulatory requirements.
Manufactured by Amgen Inc., produced under strict quality control standards to ensure biosimilarity with reference product Stelara.
Product available under careful cold chain handling to maintain stability of the biologic monoclonal antibody.
Administration supplies including sterile needles and syringes, sharps disposal containers often provided with autoinjector kits.
The dosing devices provide precise dosing volumes to ensure consistent therapeutic delivery.
All presentations approved by FDA as biosimilar or interchangeable biosimilar products depending on formulation.
Labeling includes prescribing information, contraindications, and warnings to guide clinical use.
Products may be dispensed under various brand names including Wezlana and other biosimilar counterparts.